SI1373259T1 - Pyridazinone aldose reductase inhibitors - Google Patents

Pyridazinone aldose reductase inhibitors

Info

Publication number
SI1373259T1
SI1373259T1 SI200230071T SI200230071T SI1373259T1 SI 1373259 T1 SI1373259 T1 SI 1373259T1 SI 200230071 T SI200230071 T SI 200230071T SI 200230071 T SI200230071 T SI 200230071T SI 1373259 T1 SI1373259 T1 SI 1373259T1
Authority
SI
Slovenia
Prior art keywords
reductase inhibitors
aldose reductase
pyridazinone aldose
pyridazinone
inhibitors
Prior art date
Application number
SI200230071T
Other languages
English (en)
Slovenian (sl)
Inventor
Banavara Lakshman Mylari
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of SI1373259T1 publication Critical patent/SI1373259T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
SI200230071T 2001-03-30 2002-01-31 Pyridazinone aldose reductase inhibitors SI1373259T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28005101P 2001-03-30 2001-03-30
PCT/IB2002/000320 WO2002079198A1 (en) 2001-03-30 2002-01-31 Pyridazinone aldose reductase inhibitors
EP02716247A EP1373259B1 (en) 2001-03-30 2002-01-31 Pyridazinone aldose reductase inhibitors

Publications (1)

Publication Number Publication Date
SI1373259T1 true SI1373259T1 (en) 2005-04-30

Family

ID=23071435

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200230071T SI1373259T1 (en) 2001-03-30 2002-01-31 Pyridazinone aldose reductase inhibitors

Country Status (44)

Country Link
US (2) US6579879B2 (zh)
EP (3) EP1373259B1 (zh)
JP (1) JP2004528319A (zh)
KR (1) KR100586138B1 (zh)
CN (1) CN1215067C (zh)
AP (1) AP2002002461A0 (zh)
AR (1) AR035798A1 (zh)
AT (3) ATE286049T1 (zh)
AU (1) AU2002226634B2 (zh)
BG (1) BG108179A (zh)
BR (1) BR0208571A (zh)
CA (1) CA2442476A1 (zh)
CZ (1) CZ20032563A3 (zh)
DE (3) DE60217930T2 (zh)
DK (2) DK1491540T3 (zh)
EA (1) EA006023B1 (zh)
EC (1) ECSP034671A (zh)
EE (1) EE200300470A (zh)
ES (2) ES2231681T3 (zh)
GE (1) GEP20053675B (zh)
HK (1) HK1061678A1 (zh)
HR (1) HRP20030752A2 (zh)
HU (1) HUP0303644A3 (zh)
IL (1) IL156462A0 (zh)
IS (3) IS2205B (zh)
MA (1) MA27003A1 (zh)
MX (1) MXPA03008850A (zh)
MY (1) MY134304A (zh)
NO (1) NO20034345L (zh)
NZ (1) NZ528406A (zh)
OA (1) OA12453A (zh)
PA (1) PA8541801A1 (zh)
PE (1) PE20030007A1 (zh)
PL (1) PL365294A1 (zh)
PT (2) PT1491540E (zh)
SI (1) SI1373259T1 (zh)
SK (1) SK11852003A3 (zh)
TN (1) TNSN02037A1 (zh)
TW (1) TWI245762B (zh)
UA (1) UA73236C2 (zh)
UY (1) UY27237A1 (zh)
WO (1) WO2002079198A1 (zh)
YU (1) YU71403A (zh)
ZA (1) ZA200304671B (zh)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1094757C (zh) 1996-07-24 2002-11-27 沃尼尔·朗伯公司 用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物
EP1236720B1 (en) * 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
HUP0303644A3 (en) * 2001-03-30 2008-06-30 Pfizer Prod Inc Pyridazinone-derivatives aldose reductase inhibitors, their use and pharmaceutical compositions containing them
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
ES2246464T3 (es) * 2002-01-09 2006-02-16 Pfizer Products Inc. Procedimiento e intermedios para agentes antidiabeticos de piridazinona.
US20040092522A1 (en) * 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US7419981B2 (en) * 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US6872833B2 (en) * 2003-04-14 2005-03-29 Hoffmann-La Roche Inc. Adenosine receptor ligands
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
WO2006028565A2 (en) * 2004-06-30 2006-03-16 Whitehead Institute For Biomedical Research Novel methods for high-throughput genome-wide location analysis
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
RU2008127501A (ru) * 2006-01-13 2010-02-20 Вайет (Us) Сульфонилзамещенные 1н-индолы в качастве лигандов 5-гидрокситриптаминовых рецепторов
RS52307B (en) * 2006-06-27 2012-12-31 Takeda Pharmaceutical Company Limited CONDENSED CYCLIC UNITS
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
KR20140091522A (ko) * 2011-09-15 2014-07-21 타이페이 메디컬 유니이버시티 심부전증 또는 신경 손상을 치료하기 위한 인돌릴 및 인돌리닐 하이드록사메이트의 용도
US9339542B2 (en) * 2013-04-16 2016-05-17 John L Couvaras Hypertension reducing composition
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
CN103739547B (zh) * 2014-01-03 2015-09-02 沈阳药科大学 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
US20180118756A1 (en) * 2015-04-14 2018-05-03 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
SI3352754T1 (sl) 2016-06-21 2021-03-31 The Trustees Of Columbia University In The City Of New York Zaviralci aldozne reduktaze in postopki njihove uporabe
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
WO2018058109A1 (en) * 2016-09-26 2018-03-29 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
WO2018102552A1 (en) 2016-11-30 2018-06-07 Case Western Reserve University Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof
CN110573154A (zh) 2017-02-06 2019-12-13 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
CA3071114A1 (en) 2017-07-28 2019-01-31 Applied Therapeutics Inc. Compositions and methods for treating galactosemia
MX2021008533A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
MX2021014443A (es) 2019-05-31 2022-01-06 Ikena Oncology Inc Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
KR20220034739A (ko) 2019-05-31 2022-03-18 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
WO2022120353A1 (en) * 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
WO1992009594A1 (en) * 1990-11-30 1992-06-11 Tsumura & Co. Chromone derivative and aldose reductase inhibitor containing the same as active ingredient
DE9290035U1 (de) 1991-03-28 1993-11-18 Pfizer Pyridazinonessigsäuren
US5834466A (en) 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
EP1017691A1 (en) * 1997-09-24 2000-07-12 Orion Corporation (Orion-Yhtyma Oy) Bisethers of 1-oxa, aza and thianaphthalen-2-ones as phospholamban inhibitors
FR2822827B1 (fr) * 2001-03-28 2003-05-16 Sanofi Synthelabo Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
HUP0303644A3 (en) * 2001-03-30 2008-06-30 Pfizer Prod Inc Pyridazinone-derivatives aldose reductase inhibitors, their use and pharmaceutical compositions containing them
CN1505514A (zh) * 2001-04-30 2004-06-16 �Ʒ� 醛糖还原酶抑制剂与环加氧酶-2抑制剂的组合
ES2246464T3 (es) * 2002-01-09 2006-02-16 Pfizer Products Inc. Procedimiento e intermedios para agentes antidiabeticos de piridazinona.

Also Published As

Publication number Publication date
DE60202452D1 (de) 2005-02-03
PT1373259E (pt) 2005-03-31
AR035798A1 (es) 2004-07-14
CN1215067C (zh) 2005-08-17
HUP0303644A2 (hu) 2004-03-01
KR20030088484A (ko) 2003-11-19
HK1061678A1 (en) 2004-09-30
HRP20030752A2 (en) 2005-06-30
PL365294A1 (en) 2004-12-27
BR0208571A (pt) 2004-03-23
IS8251A (is) 2006-01-23
NO20034345D0 (no) 2003-09-29
SK11852003A3 (sk) 2004-07-07
IS8250A (is) 2006-01-23
CZ20032563A3 (cs) 2004-05-12
US6849629B2 (en) 2005-02-01
CA2442476A1 (en) 2002-10-10
DE60202452T2 (de) 2006-02-09
UY27237A1 (es) 2002-12-31
KR100586138B1 (ko) 2006-06-07
EP1491540A1 (en) 2004-12-29
EP1491540B1 (en) 2006-12-13
EP1373259A1 (en) 2004-01-02
ATE286049T1 (de) 2005-01-15
TNSN02037A1 (fr) 2005-12-23
PE20030007A1 (es) 2003-01-28
EP1373259B1 (en) 2004-12-29
MA27003A1 (fr) 2004-12-20
NZ528406A (en) 2004-03-26
ECSP034671A (es) 2003-08-29
ATE352551T1 (de) 2007-02-15
GEP20053675B (en) 2005-11-25
BG108179A (en) 2004-09-30
EA006023B1 (ru) 2005-08-25
UA73236C2 (en) 2005-06-15
EA200300673A1 (ru) 2003-12-25
NO20034345L (no) 2003-09-29
ATE348100T1 (de) 2007-01-15
DE60217930D1 (de) 2007-03-15
IS2205B (is) 2007-02-15
IS6845A (is) 2003-06-16
DE60217930T2 (de) 2007-10-18
DE60216823T2 (de) 2007-10-04
WO2002079198A1 (en) 2002-10-10
TWI245762B (en) 2005-12-21
EP1491541B1 (en) 2007-01-24
EE200300470A (et) 2004-02-16
DK1491540T3 (da) 2007-03-26
DK1373259T3 (da) 2005-03-29
ZA200304671B (en) 2004-06-25
YU71403A (sh) 2006-05-25
PA8541801A1 (es) 2002-10-28
CN1500087A (zh) 2004-05-26
US20030162784A1 (en) 2003-08-28
US20020143017A1 (en) 2002-10-03
ES2231681T3 (es) 2005-05-16
US6579879B2 (en) 2003-06-17
IL156462A0 (en) 2004-01-04
DE60202452C5 (de) 2006-11-23
OA12453A (en) 2006-05-24
EP1491541A1 (en) 2004-12-29
ES2274369T3 (es) 2007-05-16
MXPA03008850A (es) 2003-12-04
DE60216823D1 (de) 2007-01-25
MY134304A (en) 2007-12-31
JP2004528319A (ja) 2004-09-16
AU2002226634B2 (en) 2007-01-25
PT1491540E (pt) 2007-01-31
AP2002002461A0 (en) 2002-06-30
HUP0303644A3 (en) 2008-06-30

Similar Documents

Publication Publication Date Title
IL156462A0 (en) Pyridazinone aldose reductase inhibitors
AU2002250394A1 (en) Rho-kinase inhibitors
AU2002245709A1 (en) Rho-kinase inhibitors
AU2002357117A8 (en) Simplified eukaryotic nitrate reductase
PL363391A1 (en) Phthalayinone-piperidino-derivatives as pde4 inhibitors
AU4217201A (en) Tri-aryl-substituted-ethane pde4 inhibitors
IL158099A0 (en) Amplifier
GB2406009B (en) Amplifier
AU2003302588A1 (en) Phosphodiesterase 10a inhibitors
AU2002303712A1 (en) Novel telomerase inhibitors and uses therefor
AU2003244080A1 (en) Phosphodiesterase inhibitor
GB0101784D0 (en) Amplifier
EP1352911A4 (en) INHIBITORS OF THE ANGIOTENSIN CONVERSION ENZYME
GB0109278D0 (en) Enzyme inhibitors
GB0001565D0 (en) Dihydrofolate reductase inhibitors
GB2381977B (en) Amplifiers
GB0116458D0 (en) Amplifier
GB0120882D0 (en) Amplifier
GB0110854D0 (en) Amplifier
GB0104691D0 (en) Enzyme inhibitor
GB0102194D0 (en) Enzyme inhibitors
GB0109145D0 (en) Enzyme inhibitors
GB0101537D0 (en) Enzyme inhibitors
GB0102018D0 (en) Enzyme inhibitors
GB0106564D0 (en) Enzyme inhibitors